Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
45.04
USD
|
+0.24%
|
|
+13.14%
|
+63.78%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
406.5
|
509.9
|
1,357
|
716.3
|
1,588
|
2,643
|
-
|
-
|
Enterprise Value (EV)
1 |
166.7
|
509.9
|
1,357
|
716.3
|
1,588
|
2,643
|
2,643
|
2,643
|
P/E ratio
|
-6.18
x
|
-6
x
|
-18.4
x
|
-5.3
x
|
-9.17
x
|
-13.9
x
|
-13
x
|
-13.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.1
x
|
17
x
|
27.6
x
|
17.2
x
|
36.1
x
|
69
x
|
48.1
x
|
33.1
x
|
EV / Revenue
|
13.1
x
|
17
x
|
27.6
x
|
17.2
x
|
36.1
x
|
69
x
|
48.1
x
|
33.1
x
|
EV / EBITDA
|
-7.07
x
|
-
|
-15.3
x
|
-4.5
x
|
-10.3
x
|
-13.8
x
|
-15
x
|
-25.2
x
|
EV / FCF
|
-6.23
x
|
-6.28
x
|
-22.4
x
|
-4.55
x
|
-10.9
x
|
-15.3
x
|
-13.9
x
|
-14.9
x
|
FCF Yield
|
-16.1%
|
-15.9%
|
-4.46%
|
-22%
|
-9.21%
|
-6.52%
|
-7.17%
|
-6.7%
|
Price to Book
|
3.1
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
28,870
|
29,089
|
42,672
|
46,303
|
57,733
|
58,688
|
-
|
-
|
Reference price
2 |
14.08
|
17.53
|
31.80
|
15.47
|
27.50
|
45.04
|
45.04
|
45.04
|
Announcement Date
|
3/12/20
|
3/16/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
31.13
|
29.94
|
49.11
|
41.59
|
43.95
|
38.33
|
54.99
|
79.85
|
EBITDA
1 |
-57.52
|
-
|
-88.73
|
-159.1
|
-154.2
|
-192
|
-176.1
|
-104.9
|
EBIT
1 |
-58.66
|
-75.88
|
-89.98
|
-160
|
-156.5
|
-198.6
|
-217.2
|
-223.1
|
Operating Margin
|
-188.41%
|
-253.41%
|
-183.22%
|
-384.84%
|
-356.22%
|
-518.08%
|
-394.95%
|
-279.43%
|
Earnings before Tax (EBT)
1 |
-54.96
|
-85.01
|
-66.58
|
-130.2
|
-151.7
|
-181.6
|
-209
|
-214
|
Net income
1 |
-55.15
|
-85.51
|
-66.82
|
-131.2
|
-154.9
|
-190.8
|
-222.2
|
-227.2
|
Net margin
|
-177.15%
|
-285.59%
|
-136.06%
|
-315.48%
|
-352.56%
|
-497.86%
|
-404.16%
|
-284.53%
|
EPS
2 |
-2.280
|
-2.920
|
-1.730
|
-2.920
|
-3.000
|
-3.230
|
-3.461
|
-3.297
|
Free Cash Flow
1 |
-65.27
|
-81.19
|
-60.5
|
-157.5
|
-146.2
|
-172.3
|
-189.6
|
-177.2
|
FCF margin
|
-209.65%
|
-271.14%
|
-123.19%
|
-378.7%
|
-332.65%
|
-449.38%
|
-344.78%
|
-221.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/16/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
13.67
|
14.71
|
11.66
|
12.68
|
6.581
|
10.67
|
13.5
|
10.48
|
11.03
|
8.939
|
8.342
|
7.988
|
8.61
|
8.089
|
6.078
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-46.97
|
-47.4
|
-46.89
|
-43.94
|
-41.7
|
-
|
EBIT
1 |
-22.52
|
-22.86
|
-27.07
|
-31.11
|
-48.2
|
-53.66
|
-36.75
|
-33.88
|
-38.37
|
-47.54
|
-47.86
|
-50.99
|
-53.16
|
-56.41
|
-
|
Operating Margin
|
-164.75%
|
-155.45%
|
-232.29%
|
-245.25%
|
-732.34%
|
-503.12%
|
-272.26%
|
-323.45%
|
-347.76%
|
-531.85%
|
-573.72%
|
-638.34%
|
-617.45%
|
-697.41%
|
-
|
Earnings before Tax (EBT)
1 |
-14.86
|
-14.28
|
-18.78
|
-5.583
|
-24.29
|
-81.58
|
-40.2
|
-30.54
|
-21.89
|
-59.12
|
-44.38
|
-48.13
|
-50.36
|
-53.67
|
-
|
Net income
1 |
-14.85
|
-14.42
|
-18.89
|
-5.714
|
-24.62
|
-81.97
|
-39.74
|
-32.03
|
-23.01
|
-60.15
|
-45.03
|
-48.68
|
-52.06
|
-56.03
|
-
|
Net margin
|
-108.66%
|
-98.04%
|
-162.1%
|
-45.05%
|
-374.03%
|
-768.54%
|
-294.4%
|
-305.78%
|
-208.57%
|
-672.93%
|
-539.74%
|
-609.44%
|
-604.64%
|
-692.68%
|
-
|
EPS
2 |
-0.3900
|
-0.3400
|
-0.4300
|
-0.1300
|
-0.5300
|
-1.810
|
-0.8600
|
-0.6600
|
-0.4300
|
-1.090
|
-0.7918
|
-0.8473
|
-0.8964
|
-0.9482
|
-0.8900
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
2/28/22
|
5/9/22
|
8/8/22
|
11/3/22
|
2/28/23
|
5/4/23
|
8/7/23
|
11/2/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
240
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-65.3
|
-81.2
|
-60.5
|
-157
|
-146
|
-172
|
-190
|
-177
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-31.9%
|
-46.6%
|
-51.4%
|
-62.5%
|
-73.6%
|
-49.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
4.550
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.600
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.22
|
1.29
|
0.87
|
7.59
|
3.98
|
5.27
|
5.94
|
6.51
|
Capex / Sales
|
7.14%
|
4.3%
|
1.77%
|
18.24%
|
9.06%
|
13.74%
|
10.8%
|
8.15%
|
Announcement Date
|
3/12/20
|
3/16/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
45.04
USD Average target price
60.45
USD Spread / Average Target +34.22% Consensus |
1st Jan change
|
Capi.
|
---|
| +63.78% | 2.64B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|